l General Information |
Product Name | CUDC-907 |
General description | Fimepinostat is a dual PI3K and HDAC inhibitor for PI3Kα and HDAC1/2/3/10. |
Synonym | N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5 carboxamide; Fimepinostat |
Purity | ≥98.0%(HPLC) | CAS Number | 1339928-25-4 |
Formula | C23H24N8O4S | Molecular Weight | 508.55 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol
Actions | Fimepinostat is an orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon oral administration, fimepinostat inhibits the activity of both PI3K class I isoforms and HDAC, thereby preventing the activation of the PI3K-AKT-mTOR signal transduction pathway that is often overactivated in many cancer cell types. This may prevent growth of PI3K and/or HDAC-expressing tumor cells. CUDC-907 shows an increased inhibition of tumor cell growth and induction of apoptosis when compared to inhibitors that target either PI3K or HDAC. CUDC-907 is a dual PI3K and HDAC inhibitor for PI3Kα and HDAC1/2/3/10 with IC50 of 19 nM and 1.7 nM/5 nM/1.8 nM/2.8 nM, respectively. |
Application | Fimepinostat has been used in trials studying the treatment of Lymphoma, Solid Tumors, BREAST CANCER, Multiple Myeloma, and NUT Midline Carcinoma, among others. |
l Storage |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This
product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
